ClinicalTrials.gg
RecruitingNCT07490860Updated Oct 29, 2026

A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial

An interventional study of Educational Intervention and Survey Administration in Lung Carcinoma, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 50 Years to 77 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Screening

How we know

Updated Oct 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
50 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center — 6 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Fred Hutchinson Cancer Center.

Planned enrollment
8th of 12
45 · median 52
Started
2026
with 3 others
No phase
8 of 13
4 open now
Registered
11th of 13
by date

Among the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 with no phase, and was the 11th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 77 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (within 15 years) who are aged 50-80 with at least a 20 pack-year smoking history. LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice-based LCS decision-making support intervention in this trial has been specifically tailored to meet the needs of Black individuals. It is designed to reduce racial unfairness by promoting trust, shared understanding, and empowerment in clinical decision making while addressing the social and historical circumstances of health inequalities. This may be an effective way to increase LCS among Black community members.

Read the detailed description

OUTLINE:

Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.

After completion of study intervention, participants may be followed up at 90 days.

03

Conditions studied

  • Lung Carcinoma

Browse trials for

04

Who can participate

Ages eligible
50 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Identify as Black or African American
  • Between ages 50-77
  • Self-reported 20-pack year smoking history
  • Ongoing commercial tobacco use within the past 15 years
  • Proficiency in the English language

Exclusion criteria

Exclusion Criteria:

  • Has a documented chest CT within the past one year
  • Personal history of lung cancer or symptoms associated with lung cancer
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Screening [Lung cancer screening (LCS) decision-making support session]

    Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.

    Other: Educational Intervention · Other: Survey Administration · Other: Interview · Other: Electronic Health Record Review

Interventions

  • OtherEducational Intervention

    Attend LCS decision-making support session

  • OtherSurvey Administration

    Ancillary studies

  • OtherInterview

    Ancillary studies

  • OtherElectronic Health Record Review

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Intervention acceptability

    Assessed using the Acceptability of Intervention Measure (AIM). The AIM will be summarized and presented as a range of scores from 1 (low acceptability/appropriateness) to 5 (high acceptability/appropriateness).

    Time frame: At post-intervention (Day 1)

  2. Lung cancer screening knowledge

    Will be assessed using the Lung Cancer Screening Knowledge 7 question score. Pre- and post-intervention responses will be compared via Chochran-Mantel-Haenszel and Friedman tests.

    Time frame: At pre- and post-intervention (both on Day 1)

Secondary outcomes

  1. Readiness to screen

    Will be assessed using the Lung Cancer Screening Health Belief Scales. Participant responses will be summarized with the median and range of scores at pre- and post-intervention.

    Time frame: At pre- and post-intervention (both on Day 1)

  2. Medical mistrust

    Will be assessed using the Discrimination in Medical Setting and Group-Based Medical Mistrust scale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention.

    Time frame: At pre- and post-intervention (both on Day 1)

  3. Perceived smoking-related stigma

    Will be assessed using the Cataldo Lung Cancer Stigma Scale: smoking-related subscale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention.

    Time frame: At pre- and post-intervention (both on Day 1)

  4. Shared decision-making (SDM) process

    Will be assessed using the Shared Decision Making Questionnaire. Participant responses will be summarized with the median and range of scores, with 0 indicating no SDM behavior and 100 indicating ideal SDM behavior.

    Time frame: At post-intervention (Day 1)

  5. Completion of chest computed tomography (CT)

    Will assess completion of chest CT within 90 days post-intervention with no comparison.

    Time frame: Up to 90 days post-intervention

  6. Intervention acceptability and refinement

    Will recruit a subset of participants to participate in a semi-structured interview post-intervention to gain an in-depth understanding of intervention acceptability and intervention refinement, including participant perspectives about the integration of restorative justice-based lung cancer screening decision-making support. Qualitative interview data will be analyzed using a mixed inductive-deductive approach to thematic analysis.

    Time frame: At 90 days post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 0 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 24, 2026
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Dec 1, 2026
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Oct 15, 2026→Dec 1, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07490860
Collaborators
AstraZeneca, Go2 Foundation
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Matthew Triplette, MD, MPH
Contact
Mtriplet@fredhutch.org
206-667-6335
Matthew Triplette, MD, MPH
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion